We partner with leading pharmaceutical, biotechnology, and diagnostic companies to support and strengthen OCRA's mission.
As the leading ovarian cancer organization in the world, we recognize that stakeholder collaboration is key to achieving our goal of curing gynecologic cancers and ensuring the development of safe, more effective therapies. We work with our partners to fulfill our shared goals of raising awareness, supporting patients, emphasizing education, and advancing critical research and treatment options.
Partnering with OCRA helps bring your clinical work full circle, supporting patients through every stage of their journeys. By collaborating with us, industry partners gain a better understanding of patient needs, helping ensure developments that address their concerns, while gaining an increased focus on real-world data.
We have a number of year-round sponsorship and support opportunities for partners, from patient support and education, to advocacy, to our International Conference, as well as our Gynecologic Cancer Collaborative. OCRA also engages with partners to increase awareness through unbranded communications campaigns and opportunities to elevate the patient voice in therapy development. Please contact us if you wish to learn more about our work and how we can partner to better serve and support the gynecologic cancer community.
At present, OCRA does not engage with partners for paid advertisements on our website or digital/print publications and newsletters. We do have opportunities for brand awareness and advertisements via our International Gynecologic Cancer Conference.
For more information, please email info@ocrahope.org.
This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued
OCRA’s Annual Advocacy Day Draws Survivors and Caregivers from Across the Country More than 120 gynecologic cancer survivors, caregivers, researchers and supporters from nearly forty states filled the halls of the U.S. Capitol on Tuesday, March 17—dressed in teal, the color of ovarian cancer awareness—as Ovarian Cancer Research Alliance (OCRA) held its annual Spring Advocacy Day. The … Continued
Get email updates about research news, action alerts, and ways to join the fight.
